Alex Schuth

Alex Schuth is Chief Operating and Financial Officer of Denali Therapeutics. He is a co-founder of the company and responsible for portfolio management, corporate development, and the legal group.

Since 2015, Alex and his team have helped build and advance a broad portfolio of therapeutic drug candidates from discovery stage to clinical development and established over 30 collaborations with partners in academia and industry to accelerate the discovery and development of medicines for neurodegenerative diseases.

Alex previously held various operational and leadership positions during a 10-year tenure at Genentech, including Head of Neuroscience Partnering, and contributed to the growth and success of Genentech’s pipeline across several therapeutic areas. Before joining Genentech, Alex worked in Merrill Lynch’s investment banking group in London, where his responsibilities included executing equity capital market transactions.

Alex holds an M.D. degree from the Charite Medical School at the Humboldt University in Berlin, Germany, and an M.B.A. from the Wharton School of the University of Pennsylvania.